Refractory Tumors Completed Phase 1 Trials for DB00853 (Temozolomide)

Also known as: Refractory Tumor

IndicationStatusPhase
DBCOND0036368 (Refractory Tumors)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00412503Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and AdolescentsTreatment